Publications on People Living With HIV (PLHIV)

The report aims to demonstrate the role of media in reflecting and perpetuating stigma and discrimination against key affected population and people living with HIV.

This paper documents the recent developments, opportunities and challenges in intellectual property rights and access to affordable medicines in China.

Behavioral sentinel surveillance (BSS) has been conducted by NCHADS to document behavior changes among sentinel groups since 1997.

Country posters of 18 countries prepared by UNAIDS Asia-Pacific Regional Support Team and HIV and AIDS Data Hub for Asia-Pacific for the 10th UNAIDS Asia-Pacific Regional Management Meeting, Bangkok, 16-17 November 2013

This policy brief examines the challenges to affordable HIV treatment access in MICs amongst people living with HIV (PLHIV) and key populations.

This document describes a process that would enable countries to respond more effectively to their respective HIV epidemics.

Myanmar recognizes the HIV epidemic as one of its most serious health challenges: AIDS is one of the priority diseases in the National Health Plan. The country is committed to achieving a series of national and global strategic targets.

The HLM targets and UNSC Resolution 1983 provide an opportunity to scale up universal access to HIV and AIDS related services for all uniformed service personnel and their family members and for people living with HIV and the key populations at higher risk of HIV with whom uniformed services personnel interact.

This study is intended to inform the efforts of governments and civil society to strengthen the enabling legal environment for HIV responses. The focus is both on the content of protective laws and issues that arise in effective implementation of protective laws. Ensuring protective legislation is in place is insufficient – attention must also be paid to how the law is implemented and enforced.

UNITAID's mission has remained constant over the years. It increases access to treatment for HIV/ AIDS, TB and malaria for people in developing countries by leveraging price reductions of quality drugs and diagnostics, which currently are unaffordable for most developing countries, and to accelerate the pace at which they are made available.